The biotech company 23andMe has a big mess to clean up after its entire board resigned to protest its CEO’s plans to take the genetic-testing company private. Penny stocks, which often trade in low volumes, tend to be volatile. The company went public in 2021 via a merger with a special purpose acquisition company.